(Reuters)—Amgen Inc’s biosimilar form of AbbVie Inc.’s adalimumab (Humira) arthritis drug, the world’s top-selling medicine, is similarly potent and safe as the original product, according to a preliminary review by staff members of the U.S. Food and Drug Administration (FDA). The assessment precedes an all-day meeting on Tuesday of an independent panel of medical advisers…
Articles by Natasha Yetman
U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants
NEW YORK (Reuters)—A U.S. judge has slashed a $500 million verdict against Johnson and Johnson and its DePuy unit over allegedly defective metal-on-metal Pinnacle hip implants to approximately $151 million. On Tuesday, U.S. District Judge Ed Kinkeade in the Northern District of Texas says he was compelled to reduce the verdict under a Texas state…
GI Side Effects Leading Reason for Bisphosphonate Nonadherence
NEW YORK (Reuters Health)—Gastrointestinal side effects are the most common reason osteoporotic women cite for nonadherence to oral bisphosphonate therapy, according to a new survey. “Our findings highlight the importance of low tolerability to nonadherence with osteoporosis therapy and underlines patients’ poor awareness and suboptimal physicians’ involvement in conveying the importance of this therapy,” Dr….
RA Choice: A Tool to Improve Patient Literacy
Doctor-patient communication is critical for successfully treating rheumatoid arthritis. But a majority of RA patients report suboptimal shared decision making, sometimes due to language barriers, lack of time, limited health literacy and other factors. A recent pilot study sought to improve patient understanding and communication by employing an adapted medication guide and decision aid during clinical visits. Use of the tool, RA Choice, resulted in an increase in patient knowledge, and a majority of clinicians found it helpful…
Spanish Drugmaker Fears Disruption if EMA Moves from Britain
MADRID (Reuters)—The likely relocation of the European Medicines Agency (EMA) from London threatens to disrupt the approval of new drugs and is a medium and long-term worry for top Spanish drugmaker Almirall, its chief executive says on Monday. The EMA, Europe’s equivalent the U.S. Food and Drug Administration, approves medicines for all European Union countries…
Statin Use Tied to Lower Risk of Inflammatory Bowel Disease
NEW YORK (Reuters Health)—Statin use is associated with a lower risk of developing inflammatory bowel disease (IBD), especially Crohn’s disease in older patients, new research suggests. “Prior studies have suggested that statins can decrease inflammation and may improve IBD in patients who already have the disease. To our knowledge, this is the first study to show…
Family History Biggest Predictor of Heart Attacks in People with Psoriasis
(Reuters Health)—People with psoriasis, a chronic inflammatory disease, are more likely to have heart attacks and strokes when they have a family history of cardiovascular problems, a Danish study suggests. Psoriasis wasn’t associated with higher risk of heart attacks or strokes when people with the skin condition didn’t have a family history of cardiovascular disease,…
Doctors Blame Many Factors for Futile Care, Themselves Included
(Reuters Health)—Doctors who were asked about causes of inappropriate care at the end of life didn’t have to look far to place blame. They blamed themselves. Australian researchers interviewed 96 physicians from 10 medical specialties and asked them to describe situations when patients received end of life care that the doctors felt was inappropriate. Futile…
California Insurance Commissioner Urges U.S. to Block Anthem-Cigna Deal
(Reuters)—California’s insurance commissioner on Thursday urged the U.S. Department of Justice (DOJ) to block health insurer Anthem Inc.’s acquisition of Cigna Corp., saying he is concerned it will raise premiums in the state. Dave Jones, who as insurance commissioner in California does not have authority to approve the deal, says he believes his recommendation will…
French Prosecutors Open Probe into Fatal Drug Trial
PARIS (Reuters)—Paris prosecutors said on Tuesday they have begun an involuntary manslaughter investigation into a failed drug trial that left one dead and five hospitalized in January. The prosecutors’ office said the investigation had been opened to determine whether there was a criminal element in any mistakes made or whether it was simply the result…
- « Previous Page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- …
- 97
- Next Page »